Showing 4631-4640 of 20465 results for "".
- Sacituzumab Tirumotecan Plus Pembrolizumab in PD-L1-Positive NSCLChttps://reachmd.com/news/sacituzumab-tirumotecan-plus-pembrolizumab-in-pd-l1-positive-nsclc/2487321/Key Takeaways Progression-free survival favored the combination on hazard ratio analysis at the prespecified interim review. The progression-free survival advantage was reported as broadly consistent across PD-L1 tumor proportion score subgroups.
- AHS Preview Highlights New Treatments, Biomarkers, and Gut-Brain Topicshttps://reachmd.com/news/ahs-preview-highlights-new-treatments-biomarkers-and-gut-brain-topics/2487316/Key Takeaways The meeting will bring more than 350 abstracts and five plenary sessions to Orlando from June 4-7, 2026. The highlighted themes are treatment innovation, biomarkers and personalized medicine, and gut-brain axis topics. The schedu
- Skin Cancer Champions Announces Patient Advocacy Summithttps://reachmd.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t
- Simultaneous Skin Pinch Blepharoplasty, Full-Field Er:YAG Resurfacing Shows Favorable Outcomes for Lower Eyelid Rejuvenationhttps://reachmd.com/news/simultaneous-skin-pinch-blepharoplasty-full-field-eryag-resurfacing-shows-favorable-outcomes-for-lower-eyelid-rejuvenation/2487318/A combined approach incorporating lower eyelid skin pinch blepharoplasty and full-field erbium:YAG laser resurfacing demonstrated favorable aesthetic outcomes with a low complication rate in a retrospective case series published online ahead of print in the Journal of Cosmetic and Laser Thera
- Semaglutide Meta-Analysis Finds Lower Mortality and Kidney Eventshttps://reachmd.com/news/semaglutide-meta-analysis-finds-lower-mortality-and-kidney-events/2487307/Key Takeaways Semaglutide was linked with lower mortality in the pooled analysis and with fewer major adverse cardiovascular events than placebo. Lower rates were also reported for nonfatal myocardial infarction, worsening heart failure, and kidney out
- Anselamimab Misses Overall Endpoint, Signals Kappa Benefit In CAREShttps://reachmd.com/news/anselamimab-misses-overall-endpoint-signals-kappa-benefit-in-cares/2487306/Key Takeaways Anselamimab was not associated with a significant advantage on the primary hierarchical composite endpoint in the full randomized population. Among patients with kappa isotype, lower mortality, fewer cardiovascular hospitalizations, and b
- Efgartigimod Shows Rapid Short-Term Responses in Juvenile MG Cohorthttps://reachmd.com/news/efgartigimod-juvenile-mg/2487299/Key Takeaways Improvement was observed by week 1 and continued through week 4 across the short observation window. Minimal symptom expression was reported in 66.7% (8/12) of evaluable patients by week 4. Patients remained on background immunos
- Aflibercept 8 mg Sustains 96-Week Outcomes in PULSAR nAMD Trialhttps://reachmd.com/news/aflibercept-8-mg-sustains-96-week-outcomes-in-pulsar-namd-trial/2487292/Key Takeaways Week 96 visual and anatomic outcomes were maintained, and BCVA differences versus 2q8 met the noninferiority criteria specified for the primary end point at week 48. Extended intervals were common with aflibercept 8 mg among patients comp
- Ruxolitinib Cream in Lichen Sclerosus: Phase 2 Trial Resultshttps://reachmd.com/news/ruxolitinib-cream-in-lichen-sclerosus-phase-2-trial-results/2487276/Key Takeaways Greater improvement in total Clinical Lichen Sclerosus Score was observed with ruxolitinib than with vehicle at week 12. The proportion reaching Itch NRS4 at week 12 was similar in the ruxolitinib and vehicle groups. Application-
- Melatonin Falls Short In Neuropathic Pain Crossover Trialhttps://reachmd.com/news/melatonin-falls-short-in-neuropathic-pain-crossover-trial/2487281/Key Takeaways Melatonin did not show a primary pain advantage over placebo in the crossover comparison. No secondary outcomes differed significantly, including measures of sleep, mood, and quality of life. Treatment-emergent adverse events wer